Frequently Asked Questions

Federal prosecutors have charged numerous New York pharmacy owners and employees with criminal violations relating to OTC card exchanges and nominal benefits. Because these practices are widespread, providers should act immediately to limit their exposure as the crackdown expands.

Government’s Healthcare Fraud Investigation

At the time of this update, the federal government has filed criminal charges against numerous pharmacy owners and employees for violations of the Anti-Kickback Statute and Healthcare Fraud relating to OTC card exchanges and nominal benefits, including $3 supermarket coupons, $2 in-store credits, and waivers of $3 copayments.

The government alleges in these cases that patients, pharmacies, and physicians all participated in a loop of bribery, referrals and billing fraud. These charges are severe and carry prison terms of up to 10 years’ incarceration.

Healthcare Fraud Based on OTC Benefits

Specifically, the government alleges that patients were paid kickbacks by pharmacies in the form of OTC and other common benefits, such as co-pay waivers.

The pharmacies then allegedly referred their patients to physicians, who wrote medically unnecessary prescriptions for high-reimbursing drugs and DME. The patients, in turn, returned to the referring pharmacies, where the prescriptions were filled to the tune of tens of millions of dollars in federal reimbursement.

Although the government has yet to unveil charges against physicians who participated in the scheme, those charges have either been filed under seal and the physicians are cooperating, or they will be filed publicly soon.

Healthcare Fraud Theory of Prosecution

Notably, the theory of prosecution in these cases is incredibly broad.  For example, the government alleges that “a common means of providing kickbacks and bribes to Medicare beneficiaries and Medicaid recipients and facilitating fraud schemes for medically unnecessary medications is to fail to charge such individuals the copayments due for their prescriptions.”

On the other hand, the OIG has recognized that copay waivers may be appropriate based on individualized assessments of financial need, and has never charged a patient with receiving a so-called bribe in the form of a co-pay waiver.

Accordingly, the sweeping charging theory in these cases means that a pharmacist may be criminally charged if he or she has waived copays or offered other nominal benefits to customers, such as accepting OTC cards for non-eligible items, who then filled medically unnecessary prescriptions, irrespective of whether the pharmacist knew the order lacked medical necessity.

This exposure is troubling for a number of reasons. First, pharmacists typically have no insight whatsoever into whether a prescribed drug is medically necessary to treat a patient’s condition. Second, the circumstances in which a pharmacist can legally refuse to fill a prescription vary, and may depend on state law. Third, despite the prevalence of co-pay waivers and OTC violations throughout the industry, federal prosecutors are using data to target “outlier” pharmacies without regard to customer base or underlying patient conditions.

HLA Specializes in Healthcare Fraud Defense

In short, if your pharmacy has offered nominal benefits involving OTC cards and co-pay waivers to customers, you may have criminal exposure. There are a number of immediate steps that clients can take to better understand and limit that risk. At Health Law Alliance, our experienced healthcare defense attorneys have represented numerous clients under federal investigation for the practices described in this article. Our firm’s mission is simple: use unmatched experience and insight to defend our clients against insurance conglomerates, the federal government, and state agencies. We used to work for them. Now let us fight for you. Contact us today for a COMPLIMENTARY consultation. We can help.  

MORE ARTICLES BY CATEGORY

Get a Free Case REVIEW

100% Confidential & Secure. Your details are safe with us.

We'll speak soon!

In the meantime, why not find out more about us or visit our blog.

Alternatively, give us a call at (800) 345 - 4125

Oops! Something went wrong while submitting the form.

HLA's Diana Yastrovskaya Featured on Live TV for PBM Expertise

The feature underscores HLA’s mission to elevate thought leadership within the healthcare space and provide trusted expertise on issues that directly impact patients, providers, and policymakers.

Read More >>

By Appointment Only: How DME Suppliers Can Prevent Unexpected DME License Revocations

DME suppliers can prevent unexpected and costly license revocations by strategically applying with a "By Appointment Only" designation. This article explores the common compliance trap of failing unannounced site visits due to conflicts between standard pharmacy operating hours and Medicare's "posted hours" requirement for DME suppliers. "By Appointment Only" status is a crucial safeguard, which suppliers can take to implement to protect their DME billing privileges.

Read More >>

Resolving Prescription “Red Flags” Is No Longer Optional: Federal Scrutiny Tightens on Controlled-Substance Dispensing

Pharmacists must resolve “red flags” under the Controlled Substances Act’s corresponding-responsibility requirements before dispensing controlled substances. Overlooking warning signs, such as cash-paid, high-dose opioid prescriptions—can now trigger False Claims Act liability and massive penalties, as demonstrated by Walgreens’ $350 million settlement in April 2025.

Read More >>

9th Circuit’s Landmark EKRA Ruling—What Providers Should Know

On July 11, 2025, the 9th Circuit upheld a laboratory operator’s convictions for violating EKRA by paying marketing agents to mislead providers into providing patient referrals for medically unnecessary blood tests. In this article, we analyze the 9th Circuit’s ruling and what it means for the future of EKRA enforcement.

Read More >>